News Releases

Dr. Cohen Pfeffer Brings More Than a Decade of Clinical Development Leadership, Including Deep Experience with Enzyme Replacement Therapies for Rare Pediatric Neurodegenerative Disorders SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 3, 2026-- Spruce Biosciences, Inc.

Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul.

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE)-- Spruce Biosciences, Inc.  (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D.,

Inclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) SOUTH SAN FRANCISCO, Calif.

Dr. Jurecka Brings Deep Enzyme Replacement Therapy and Rare Disease Experience to Lead Medical Affairs and Scientific Engagement Ahead of Potential U.S. FDA Approval of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) SOUTH SAN

Appointments Further Strengthen Spruce’s Commercial and Financial Capabilities as the Company Approaches a Potential U.S. FDA Approval and Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) SOUTH SAN FRANCISCO,

Data Highlight TA-ERT’s Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved Therapies Treatment With Weekly TA-ERT Demonstrated Rapid and Durable Normalization of CSF Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint

Nicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 28, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the

Long-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB Strengthened Leadership Team Across Commercial, Clinical Development, and Regulatory Functions to Support BLA